Christopher Cabell
President & Head of R&D · Inhibikase Therapeutics, Inc.
Individual
- 2025
- Feb 25, 2026
- 3
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Christopher Cabell files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Sands Capital Life Sciences Pulse Fund II, L.P. - $3.00M in IKT purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Christopher Cabell?
Christopher Cabell is a corporate insider, tracked as President & Head of R&D of Inhibikase Therapeutics, Inc. (IKT). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Christopher Cabell last file a Form 4?
The most recent primary Form 4 on record is dated 25 February 2026, one of 3 filings going back to 2025.
